A detailed history of Trexquant Investment LP transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Trexquant Investment LP holds 159,261 shares of NRIX stock, worth $3.12 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
159,261
Previous 238,582 33.25%
Holding current value
$3.12 Million
Previous $4.98 Million 28.2%
% of portfolio
0.05%
Previous 0.08%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$18.93 - $25.69 $1.5 Million - $2.04 Million
-79,321 Reduced 33.25%
159,261 $3.58 Million
Q2 2024

Aug 13, 2024

BUY
$12.02 - $21.3 $308,950 - $547,473
25,703 Added 12.07%
238,582 $4.98 Million
Q1 2024

May 14, 2024

BUY
$7.77 - $15.66 $416,168 - $838,765
53,561 Added 33.62%
212,879 $3.13 Million
Q4 2023

Feb 09, 2024

BUY
$4.25 - $10.71 $302,821 - $763,108
71,252 Added 80.91%
159,318 $1.64 Million
Q3 2023

Nov 13, 2023

BUY
$7.86 - $10.08 $253,186 - $324,696
32,212 Added 57.67%
88,066 $692,000
Q2 2023

Aug 11, 2023

BUY
$8.7 - $13.28 $183,630 - $280,300
21,107 Added 60.74%
55,854 $557,000
Q1 2023

May 15, 2023

BUY
$8.56 - $13.26 $65,886 - $102,062
7,697 Added 28.45%
34,747 $308,000
Q4 2022

Feb 13, 2023

BUY
$9.86 - $14.59 $20,351 - $30,113
2,064 Added 8.26%
27,050 $297,000
Q3 2022

Nov 14, 2022

BUY
$12.33 - $19.81 $180,461 - $289,939
14,636 Added 141.41%
24,986 $326,000
Q2 2022

Aug 11, 2022

SELL
$7.88 - $14.82 $267,746 - $503,553
-33,978 Reduced 76.65%
10,350 $131,000
Q1 2022

May 13, 2022

BUY
$12.94 - $29.65 $319,566 - $732,236
24,696 Added 125.79%
44,328 $621,000
Q4 2021

Feb 14, 2022

BUY
$26.43 - $34.5 $518,873 - $677,304
19,632 New
19,632 $568,000
Q2 2021

Aug 12, 2021

SELL
$24.21 - $35.89 $298,678 - $442,774
-12,337 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$26.98 - $50.17 $332,852 - $618,947
12,337 New
12,337 $384,000

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $923M
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.